Tadalafil Once Daily Improves Ejaculatory Function, Erectile Function, and Sexual Satisfaction in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Erectile Dysfunction: Results from a Randomized, Placebo- and Tamsulosin-Controlled, 12-Week Double-Blind Study

Journal of Sexual Medicine

Volumn 10, Issue 3, 2013, Pages 857-865

  Giuliano, François ^a,b   Oelke, Matthias ^c   Jungwirth, Andreas ^d   Hatzimouratidis, Konstantinos ^e   Watts, Steven ^f   Cox, David ^f   Viktrup, Lars ^f  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d EMCO Private Clinic   (Austria)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Alpha Adrenergic Blockers; Benign Prostatic Hyperplasia; Ejaculation; Ejaculatory Dysfunction; Erectile Dysfunction; Lower Urinary Tract Symptoms; Orgasm; Phosphodiesterase Type 5 Inhibitors; Sexual Function

Indexed keywords

PLACEBO; TADALAFIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EJACULATION; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGASM; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SEXUAL SATISFACTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84874680894     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12039     Document Type: Article

References (32)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
2. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S, Bosch JL. Correlates for erectile and ejaculatory dysfunction in older Dutch men: A community-based study. J Am Geriatr Soc 2001;49:436-442.
3. Rosen RC. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int 2006;97(suppl 2):29-33.
4. Vallancien G, Emberton M, Harving N, van Moorselaar RJ. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257-2261.
5. Colpi G, Weidner W, Jungwirth A, Pomerol J, Papp G, Hargreave T, Dohle G. EAU guidelines on ejaculatory dysfunction. Eur Urol 2004;46:555-558.
6. Rosen RC, Fitzpatrick JM. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2009;104:974-983.
7. Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I. Current benign prostatic hyperplasia treatment: Impact on sexual function and management of related sexual adverse events. Int J Clin Pract 2011;65:1005-1013.
8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006;66:287-301.
9. Hofner K, Claes H, de Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-341.
10. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005;95:103-109.
11. Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 2007;19:480-485.
12. Michel MC, Meissner A. Can open-label studies demonstrate efficacy in improving sexual function? Int J Impot Res 2009;21:265-266.
13. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-925.
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
15. Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-244.
16. Paduch DA, Bolyakov A, Beardsworth A, Watts SD. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: Analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. BJU Int 2012;109:1060-1067.
17. Paduch D, Bolyakov A, Polzer PK, Watts S. Twelve weeks of treatment with tadalafil as needed significantly improves ejaculatory and orgasmic dysfunction in men enrolled in 17 placebo-controlled studies of erectile dysfunction. J Sex Med 2011;8(suppl 5):451-452.
18. Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006;66:210-216.
19. Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med 2011;8(suppl 4):310-315.
20. Hwa JS, Kam SC, Choi JH, Do JM, Seo DH, Hyun JS. Impact of erectile function and age in men with lower urinary tract symptoms on ejaculatory dysfunction and premature ejaculation. Int J Impot Res 2012;24:101-105.
21. American Urology Association BPH Guidelines Panel. American Urological Association (AUA) Guideline: Guideline on the Management of Benign Prostatic Hyperplasia. 2006. Available at: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines/archived-guidelines/chapt_3_appendix.pdf (accessed September 12, 2012).
22. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900.
23. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97(suppl 2):34-38.
24. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001;57:466-470.
25. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis 2011;14:143-148.
26. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin vs. alfuzosin on ejaculatory function in normal volunteers. J Urol 2006;176:1529-1533.
27. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006;13:1311-1316.
28. Kobayashi K, Masumori N, Hisasue S, Kato R, Hashimoto K, Itoh N, Tsukamoto T. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med 2008;5:2185-2190.
29. Shimizu F, Taguri M, Harada Y, Matsuyama Y, Sase K, Fujime M. Impact of dry ejaculation caused by highly selective alpha1A-blocker: Randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. J Sex Med 2010;7:1277-1283.
30. Haning RV, O'Keefe SL, Randall EJ, Kommor MJ, Baker E, Wilson R. Intimacy, orgasm likelihood, and conflict predict sexual satisfaction in heterosexual male and female respondents. J Sex Marital Ther 2007;33:93-113.
31. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): Scale development and psychometric validation. Urology 2004;64:777-782.
32. Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011;60:1010-1016.